2010 Scrip 100 - Is Anvisa a friend of innovators?
This article was originally published in Scrip
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.
Big pharma companies need to expand in fast-growing, emerging markets to offset declining returns on investment in developed countries. As the second largest emerging pharmaceutical market after China, and among the world's top 10 pharmaceutical markets overall, Brazil offers huge potential for companies to expand, writes Sita Shah.